Do You Have FSGS? The TRACTION-2 clinical research trial is evaluating an investigational drug called GFB-887 for the potential treatment of focal segmental glomerulosclerosis (FSGS). The purpose of this trial is to determine if GFB-887 is safe and may help people who have high levels of protein in their urine due to FSGS. You may qualify for this trial if you: Are 18 to 75 years of age Have been diagnosed with or are being treated for FSGS Have high levels of protein in your urine The doctor running the study will discuss these and other requirements with you. If you qualify for the trial and choose to participate: You will be in the trial for approximately 26 weeks. You will have 17 scheduled visits with the trial doctor or trial staff. You may leave the trial at any time. Your participation is completely voluntary. Currently, there is no therapy approved in the United States specifically for treating FSGS. Clinical trials are how therapeutic options for treating diseases and health conditions are explored and developed. Volunteer participants play a key role in this research. You can learn more about this trial and answer a few questions to find out if you may qualify at www.tractionclinicaltrial.com. Thank you for your time and for considering this clinical research trial. Sincerely, The TRACTION-2 Team TRACTION-2 is sponsored by Goldfinch Bio.